AR081960A1 - Compuestos heterociclicos, su preparacion y su aplicacion terapeutica - Google Patents
Compuestos heterociclicos, su preparacion y su aplicacion terapeuticaInfo
- Publication number
- AR081960A1 AR081960A1 ARP110102137A ARP110102137A AR081960A1 AR 081960 A1 AR081960 A1 AR 081960A1 AR P110102137 A ARP110102137 A AR P110102137A AR P110102137 A ARP110102137 A AR P110102137A AR 081960 A1 AR081960 A1 AR 081960A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycloalkyl
- phenyl
- preparation
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Métodos para producirlos y a los métodos para tratar o mejorar un trastorno mediado por quinasa. Composición farmacéutica.Reivindicación 1: Compuesto de fórmula (1) en el que A es fenilo; B es fenilo, piridina, o pirimidina; R1 y R2 representan independientemente uno del otro -H, -OH, un átomo de halógeno, con la condición de que R1 y R2 no son simultáneamente hidrógeno; R3, R4 y R5 son, independientemente uno del otro, -H, -(CH2)nOH, -O-alquilo C1-6, -(CH2)n-CO-heterocicloalquilo, -OH, -heterocicloalquil-(CH2)n-OH, -alquilo C1-6, -(CH2)n-heterocicloalquilo, -(CH2)n-heterocicloalquil-(CH2)n-OH, -O-(CH2)n-heterocicloalquilo, N-óxido en el que el átomo de nitrógeno pertenece a B, -O-(CH2)n-CO-heterocicloalquilo, -O-(CH2)n-OH, -O-alquilo C1-6-NR7R8, -alquilo C1-6-NR7R8; R3 y R4 forman conjuntamente con B un biciclo fusionado sustituido opcionalmente con R5 con la condición de que cuando B es fenilo, al menos dos de R3, R4 y R5 no son hidrógeno; R6 es H, -O-alquilo C1-6 o alquilo C1-6; R7 y R8 son independientemente uno del otro H o un alquilo C1-6 sustituido opcionalmente que forma opcionalmente un cicloalquilo; n es 1, 2 ó 3; X es N o C; e Y es CH o un enlace covalente; o un profármaco de éste.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305665 | 2010-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081960A1 true AR081960A1 (es) | 2012-10-31 |
Family
ID=43033247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102137A AR081960A1 (es) | 2010-06-22 | 2011-06-21 | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20130123271A1 (es) |
| EP (1) | EP2585439A1 (es) |
| JP (1) | JP2013533237A (es) |
| KR (1) | KR20130116070A (es) |
| CN (1) | CN103140480A (es) |
| AR (1) | AR081960A1 (es) |
| AU (1) | AU2011268938A1 (es) |
| BR (1) | BR112012032721A2 (es) |
| CA (1) | CA2803496A1 (es) |
| CL (1) | CL2012003637A1 (es) |
| CO (1) | CO6660505A2 (es) |
| CR (1) | CR20120653A (es) |
| DO (1) | DOP2012000317A (es) |
| EA (1) | EA201291329A1 (es) |
| EC (1) | ECSP12012354A (es) |
| GT (1) | GT201200345A (es) |
| IL (1) | IL223721A0 (es) |
| MA (1) | MA34384B1 (es) |
| MX (1) | MX2012015305A (es) |
| NI (1) | NI201200193A (es) |
| NZ (1) | NZ605022A (es) |
| PE (1) | PE20130640A1 (es) |
| SG (1) | SG186424A1 (es) |
| TN (1) | TN2012000610A1 (es) |
| TW (1) | TW201204723A (es) |
| UY (1) | UY33461A (es) |
| WO (1) | WO2011161159A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| CN105431435A (zh) * | 2013-06-07 | 2016-03-23 | 拜耳制药股份公司 | 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类 |
| EA201501175A1 (ru) * | 2013-06-10 | 2016-10-31 | Байер Фарма Акциенгезельшафт | Новые соединения для лечения злокачественного новообразования |
| CN107428693B (zh) | 2014-12-24 | 2020-05-29 | 吉利德科学公司 | 用于hiv治疗的异喹啉化合物 |
| MX2017008520A (es) | 2014-12-24 | 2018-03-01 | Gilead Sciences Inc | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| WO2017102091A1 (en) | 2015-12-18 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| US10265315B2 (en) | 2016-04-08 | 2019-04-23 | Baylor College Of Medicine | Small molecule regulators of steroid receptor coactivators and methods of use thereof |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| WO2021254464A1 (zh) * | 2020-06-19 | 2021-12-23 | 南京红云生物科技有限公司 | 取代喹唑啉类化合物、其制备方法、药物组合及应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6056684B2 (ja) | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | 点眼剤 |
| US4271143A (en) | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| US4407792A (en) | 1979-05-09 | 1983-10-04 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| EP0501523B1 (en) | 1983-11-14 | 1997-04-09 | Columbia Laboratories, Inc. | Bioadhesive compositions |
| US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| CA2386955A1 (en) | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
| CA2542329A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| RU2006139258A (ru) | 2004-04-08 | 2008-05-20 | Таргеджен, Инк. (US) | Бензотриазиновые ингибиторы киназ |
| AU2005276974B2 (en) | 2004-08-25 | 2012-08-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101155799A (zh) | 2005-03-16 | 2008-04-02 | 塔格根公司 | 嘧啶化合物和使用方法 |
| EP1878727A4 (en) * | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| US20060292203A1 (en) | 2005-06-08 | 2006-12-28 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| WO2008020203A1 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
| TW200829566A (en) | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| AU2007336893A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for PDK1 inhibition |
| WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US20100311965A1 (en) | 2007-12-28 | 2010-12-09 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| EP2381943A1 (en) | 2008-12-29 | 2011-11-02 | Fovea Pharmaceuticals | Substituted quinazoline compounds |
| EP2396324A1 (en) * | 2009-02-13 | 2011-12-21 | Fovea Pharmaceuticals | Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines as kinase inhibitors |
-
2011
- 2011-06-21 AR ARP110102137A patent/AR081960A1/es unknown
- 2011-06-21 TW TW100121689A patent/TW201204723A/zh unknown
- 2011-06-22 BR BR112012032721A patent/BR112012032721A2/pt not_active IP Right Cessation
- 2011-06-22 EA EA201291329A patent/EA201291329A1/ru unknown
- 2011-06-22 SG SG2012094173A patent/SG186424A1/en unknown
- 2011-06-22 JP JP2013515883A patent/JP2013533237A/ja not_active Withdrawn
- 2011-06-22 MX MX2012015305A patent/MX2012015305A/es not_active Application Discontinuation
- 2011-06-22 UY UY0001033461A patent/UY33461A/es unknown
- 2011-06-22 CN CN2011800407027A patent/CN103140480A/zh active Pending
- 2011-06-22 AU AU2011268938A patent/AU2011268938A1/en not_active Abandoned
- 2011-06-22 WO PCT/EP2011/060445 patent/WO2011161159A1/en active Application Filing
- 2011-06-22 EP EP11729591.5A patent/EP2585439A1/en not_active Withdrawn
- 2011-06-22 MA MA35572A patent/MA34384B1/fr unknown
- 2011-06-22 US US13/805,479 patent/US20130123271A1/en not_active Abandoned
- 2011-06-22 CA CA2803496A patent/CA2803496A1/en not_active Abandoned
- 2011-06-22 KR KR1020137001581A patent/KR20130116070A/ko not_active Application Discontinuation
- 2011-06-22 PE PE2012002466A patent/PE20130640A1/es not_active Application Discontinuation
- 2011-06-22 NZ NZ605022A patent/NZ605022A/en not_active IP Right Cessation
-
2012
- 2012-12-18 IL IL223721A patent/IL223721A0/en unknown
- 2012-12-19 CR CR20120653A patent/CR20120653A/es unknown
- 2012-12-19 DO DO2012000317A patent/DOP2012000317A/es unknown
- 2012-12-19 TN TNP2012000610A patent/TN2012000610A1/en unknown
- 2012-12-20 NI NI201200193A patent/NI201200193A/es unknown
- 2012-12-20 GT GT201200345A patent/GT201200345A/es unknown
- 2012-12-21 CL CL2012003637A patent/CL2012003637A1/es unknown
- 2012-12-21 CO CO12231930A patent/CO6660505A2/es not_active Application Discontinuation
- 2012-12-21 EC ECSP12012354 patent/ECSP12012354A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2012003637A1 (es) | 2013-07-05 |
| KR20130116070A (ko) | 2013-10-22 |
| WO2011161159A1 (en) | 2011-12-29 |
| CA2803496A1 (en) | 2011-12-29 |
| AU2011268938A1 (en) | 2013-01-24 |
| TW201204723A (en) | 2012-02-01 |
| MX2012015305A (es) | 2013-05-30 |
| CN103140480A (zh) | 2013-06-05 |
| SG186424A1 (en) | 2013-01-30 |
| DOP2012000317A (es) | 2013-04-15 |
| EA201291329A1 (ru) | 2013-05-30 |
| JP2013533237A (ja) | 2013-08-22 |
| UY33461A (es) | 2012-01-31 |
| ECSP12012354A (es) | 2013-01-31 |
| MA34384B1 (fr) | 2013-07-03 |
| PE20130640A1 (es) | 2013-03-30 |
| NZ605022A (en) | 2013-12-20 |
| NI201200193A (es) | 2013-05-13 |
| TN2012000610A1 (en) | 2014-04-01 |
| BR112012032721A2 (pt) | 2016-11-29 |
| IL223721A0 (en) | 2013-03-05 |
| EP2585439A1 (en) | 2013-05-01 |
| GT201200345A (es) | 2014-01-24 |
| CO6660505A2 (es) | 2013-04-30 |
| CR20120653A (es) | 2013-04-03 |
| US20130123271A1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
| DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| NZ715838A (en) | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof | |
| PH12015502443A1 (en) | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| MD20150019A2 (ro) | Alcoxipirazoli în calitate de activatori ai guanilat ciclazei solubile | |
| PH12015500347A1 (en) | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| NI201300074A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos. | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| EA201592082A1 (ru) | 3,4-дигидроизохинолин-2(1h)-ильные соединения | |
| IN2014MN02652A (es) | ||
| IN2014MN02657A (es) | ||
| MD20140136A2 (ro) | Inhibitori ai virusului hepatic C | |
| MY186165A (en) | New bicyclic dihydroquinoline-2-one derivatives | |
| AR117923A2 (es) | Compuestos 4-amino-6-(4-fenilo sustituido)-picolinatos y 6-amino-2-(4-fenilo sustituido)-pirimidin-4-carboxilatos y composición que los comprende | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| MX2015001099A (es) | Nuevos derivados biciclicos de piridina. | |
| AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |